What you call a "selective reading of the guide" I call an examination of Nasdaq Listing Requirements and standards for Capital Markets and making a determination as to whether or not CTIX meets those standards.
O.K. So the process is complicated and "includes discretion and discussions." Even the guide warns:
"It is important to note that even though a company’s securities meet all enumerated criteria for initial inclusion, Nasdaq may deny initial listing, or apply additional conditions, if necessary to protect investors and the public interest."
But the evidence suggest that things aren't as complicated as you purport. Consider Leo's June 8th PR in which he stated:
Cellceutix last week learned that the application remains pending due to the price of CTIX stock currently below the minimum requirement. Cellceutix wishes to reiterate its stance that it will not perform a reverse split to meet the higher share price requirement.
Leo's own words, "pending due to price" and "will not perform a reverse split," suggest share price is the reason for the delay in up-listing (Or maybe this is just my "selective reading"). He didn't mention any other problems in regard to up-listing.
"Anticipation is making me wait," but tell me again why I shouldn't speculate about CTIX's up-listing? Clinical trials are also complicated so I suppose I shouldn't speculate about them either. I'm being sarcastic, of course, but this board would be out of business with out speculation.
Market Data 
Markets 
AI
